| Year |
Citation |
Score |
| 2020 |
Bril V, Hartung HP, Lawo JP, Durn BL, Mielke O. Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) study. Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. PMID 33039291 DOI: 10.1016/J.Clinph.2020.09.001 |
0.342 |
|
| 2020 |
Breitkopf K, Aytulun A, Förster M, Kraus B, Turowski B, Huppert D, Goebels N, Hefter H, Aktas O, Metz I, Brück W, Reifenberger G, Hartung HP, Albrecht P. Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis. Frontiers in Neurology. 11: 782. PMID 32973648 DOI: 10.3389/Fneur.2020.00782 |
0.367 |
|
| 2020 |
Graf J, Albrecht P, Goebels N, Aktas O, Hartung HP. [Erratum to: Ocrelizumab for treatment of multiple sclerosis]. Der Nervenarzt. PMID 32725489 DOI: 10.1007/S00115-020-00956-3 |
0.341 |
|
| 2020 |
Sorensen PS, Sellebjerg F, Hartung HP, Montalban X, Comi G, Tintoré M. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. Brain : a Journal of Neurology. PMID 32710096 DOI: 10.1093/Brain/Awaa145 |
0.4 |
|
| 2020 |
Mares J, Hartung HP. Multiple sclerosis and COVID-19. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. PMID 32686774 DOI: 10.5507/Bp.2020.033 |
0.34 |
|
| 2020 |
Ghezzi A, Amato MP, Edan G, Hartung HP, Havrdová EK, Kappos L, Montalban X, Pozzilli C, Sorensen PS, Trojano M, Vermersch P, Comi G. The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458520930620. PMID 32539596 DOI: 10.1177/1352458520930620 |
0.351 |
|
| 2020 |
Graf J, Albrecht P, Goebels N, Aktas O, Hartung HP. [Ocrelizumab for treatment of multiple sclerosis]. Der Nervenarzt. PMID 32524163 DOI: 10.1007/S00115-020-00937-6 |
0.385 |
|
| 2020 |
Hartung HP. Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS. Neurology(R) Neuroimmunology & Neuroinflammation. 7. PMID 32503093 DOI: 10.1212/Nxi.0000000000000807 |
0.335 |
|
| 2020 |
Bittner S, Steffen F, Uphaus T, Muthuraman M, Fleischer V, Salmen A, Luessi F, Berthele A, Klotz L, Meuth SG, Bayas A, Paul F, Hartung HP, Linker R, Heesen C, et al. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. Ebiomedicine. 56: 102807. PMID 32460167 DOI: 10.1016/J.Ebiom.2020.102807 |
0.343 |
|
| 2020 |
Landmeyer NC, Bürkner PC, Wiendl H, Ruck T, Hartung HP, Holling H, Meuth SG, Johnen A. Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis. Neurology. 94: e2373-e2383. PMID 32430312 DOI: 10.1212/Wnl.0000000000009522 |
0.333 |
|
| 2020 |
Wienemann T, Müller AK, MacKenzie C, Bielor C, Weyers V, Aktas O, Hartung HP, Kremer D. Cryptococcal meningoencephalitis in an IgG-deficient patient with multiple sclerosis on fingolimod therapy for more than five years - case report. Bmc Neurology. 20: 158. PMID 32340606 DOI: 10.1186/S12883-020-01741-0 |
0.342 |
|
| 2020 |
Kremer D, Weyers V, Gruchot J, Göttle P, Hartung HP, Perron H, Küry P. Meeting report: "Human endogenous retroviruses: HERVs or transposable elements in autoimmune, chronic inflammatory and degenerative diseases or cancer", Lyon, France, november 5th and 6th 2019 - an MS scientist's digest. Multiple Sclerosis and Related Disorders. 42: 102068. PMID 32302965 DOI: 10.1016/J.Msard.2020.102068 |
0.302 |
|
| 2019 |
Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, Croze E, Aftab BT, Giovannoni G, Joshi MJ. Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. Trends in Molecular Medicine. PMID 31862243 DOI: 10.1016/J.Molmed.2019.11.003 |
0.365 |
|
| 2019 |
Haas J, Jeffery D, Silva D, Meier DP, Meinert R, Cohen J, Hartung HP. Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies. Multiple Sclerosis and Related Disorders. 36: 101335. PMID 31557679 DOI: 10.1016/J.Msard.2019.07.011 |
0.33 |
|
| 2019 |
Penner IK, Hartung HP. The dark side of the moon: looking beyond beneficial effects of cannabis use in multiple sclerosis. Brain : a Journal of Neurology. 142: 2552-2555. PMID 31497861 DOI: 10.1093/Brain/Awz234 |
0.311 |
|
| 2019 |
Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet (London, England). PMID 31495497 DOI: 10.1016/S0140-6736(19)31817-3 |
0.332 |
|
| 2019 |
Sinnecker T, Hadisurya J, Schneider-Hohendorf T, Schwab N, Wrede K, Gembruch O, Gold R, Hellwig K, Pilgram-Pastor S, Adams O, Albrecht P, Hartung HP, Aktas O, Kraemer M. Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. Bmc Neurology. 19: 190. PMID 31399069 DOI: 10.1186/S12883-019-1407-2 |
0.321 |
|
| 2019 |
Gruchot J, Weyers V, Göttle P, Förster M, Hartung HP, Küry P, Kremer D. The Molecular Basis for Remyelination Failure in Multiple Sclerosis. Cells. 8. PMID 31382620 DOI: 10.3390/Cells8080825 |
0.374 |
|
| 2019 |
Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. The Lancet. Neurology. PMID 31285147 DOI: 10.1016/S1474-4422(19)30137-1 |
0.364 |
|
| 2019 |
Kremer D, Gruchot J, Weyers V, Oldemeier L, Göttle P, Healy L, Ho Jang J, Kang T Xu Y, Volsko C, Dutta R, Trapp BD, Perron H, Hartung HP, Küry P. pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America. PMID 31213545 DOI: 10.1073/Pnas.1901283116 |
0.377 |
|
| 2019 |
Phelps R, Winston JA, Wynn D, Habek M, Hartung HP, Havrdová EK, Markowitz GS, Margolin DH, Rodriguez CE, Baker DP, Coles AJ. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458519841829. PMID 30986126 DOI: 10.1177/1352458519841829 |
0.365 |
|
| 2019 |
Schweitzer F, Laurent S, Fink GR, Barnett MH, Reddel S, Hartung HP, Warnke C. Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis. Current Opinion in Neurology. PMID 30985373 DOI: 10.1097/Wco.0000000000000701 |
0.346 |
|
| 2019 |
Cree BAC, Mares J, Hartung HP. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Current Opinion in Neurology. PMID 30985372 DOI: 10.1097/Wco.0000000000000700 |
0.342 |
|
| 2019 |
Prozorovski T, Ingwersen J, Lukas D, Göttle P, Koop B, Graf J, Schneider R, Franke K, Schumacher S, Britsch S, Hartung HP, Küry P, Berndt C, Aktas O. Regulation of sirtuin expression in autoimmune neuroinflammation: induction of SIRT1 in oligodendrocyte progenitor cells. Neuroscience Letters. PMID 30953735 DOI: 10.1016/J.Neulet.2019.04.007 |
0.365 |
|
| 2019 |
Kremer D, Göttle P, Flores-Rivera J, Hartung HP, Küry P. Remyelination in multiple sclerosis: from concept to clinical trials. Current Opinion in Neurology. PMID 30865009 DOI: 10.1097/Wco.0000000000000692 |
0.386 |
|
| 2019 |
Dietrich M, Aktas O, Hartung HP, Albrecht P. Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspects. Current Opinion in Neurology. PMID 30694926 DOI: 10.1097/Wco.0000000000000675 |
0.359 |
|
| 2019 |
Zhu B, Calabresi PA, Giovanonni G, Kapoor R, Naismith R, Hartung H, Arnold DL, Wolstencroft P, Johnson K. 200 AFFINITY: opicinumab in a targeted population of MS patients Journal of Neurology, Neurosurgery, and Psychiatry. 90. DOI: 10.1136/Jnnp-2019-Abn-2.169 |
0.396 |
|
| 2018 |
Schira J, Heinen A, Poschmann G, Ziegler B, Hartung HP, Stühler K, Küry P. Secretome analysis of nerve repair mediating Schwann cells reveals Smad-dependent trophism. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201801799R. PMID 30592632 DOI: 10.1096/Fj.201801799R |
0.311 |
|
| 2018 |
Kieseier BC, Mathey EK, Sommer C, Hartung HP. Immune-mediated neuropathies. Nature Reviews. Disease Primers. 4: 31. PMID 30310069 DOI: 10.1016/B978-012088592-3/50021-9 |
0.352 |
|
| 2018 |
Graf J, Ringelstein M, Lepka K, Schaller J, Quack H, Hartung HP, Aktas O, Albrecht P. Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518771276. PMID 30307371 DOI: 10.1177/1352458518771276 |
0.379 |
|
| 2018 |
Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518796675. PMID 30289355 DOI: 10.1177/1352458518796675 |
0.32 |
|
| 2018 |
Hughes R, Dalakas MC, Merkies I, Latov N, Léger JM, Nobile-Orazio E, Sobue G, Genge A, Cornblath D, Merschhemke M, Ervin CM, Agoropoulou C, Hartung HP. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. The Lancet. Neurology. PMID 30001923 DOI: 10.1016/S1474-4422(18)30202-3 |
0.367 |
|
| 2018 |
Lehmann HC, Compston A, Hartung HP. 150th anniversary of clinical description of multiple sclerosis: Leopold Ordenstein's legacy. Neurology. 90: 1011-1016. PMID 29807916 DOI: 10.1212/Wnl.0000000000005613 |
0.315 |
|
| 2018 |
Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, et al. Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. Annals of Clinical and Translational Neurology. 5: 346-356. PMID 29560379 DOI: 10.1002/Acn3.534 |
0.305 |
|
| 2018 |
Küry P, Nath A, Créange A, Dolei A, Marche P, Gold J, Giovannoni G, Hartung HP, Perron H. Human Endogenous Retroviruses in Neurological Diseases. Trends in Molecular Medicine. PMID 29551251 DOI: 10.1016/J.Molmed.2018.02.007 |
0.311 |
|
| 2018 |
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. The Lancet. Neurology. PMID 29545067 DOI: 10.1016/S1474-4422(18)30069-3 |
0.376 |
|
| 2018 |
Dietrich M, Helling N, Hilla A, Heskamp A, Issberner A, Hildebrandt T, Kohne Z, Küry P, Berndt C, Aktas O, Fischer D, Hartung HP, Albrecht P. Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model. Journal of Neuroinflammation. 15: 71. PMID 29514678 DOI: 10.1186/S12974-018-1111-Y |
0.341 |
|
| 2018 |
Kieseier BC, Hartung HP. Progress in Recognizing and Treating Polyneuropathy. Deutsches Arzteblatt International. 115: 81-82. PMID 29478434 DOI: 10.3238/Arztebl.2018.0081 |
0.3 |
|
| 2018 |
Ingwersen J, De Santi L, Wingerath B, Graf J, Koop B, Schneider R, Hecker C, Schröter F, Bayer M, Engelke AD, Dietrich M, Albrecht P, Hartung HP, Annunziata P, Aktas O, et al. Nimodipine confers clinical improvement in two models of experimental autoimmune encephalomyelitis. Journal of Neurochemistry. PMID 29473171 DOI: 10.1111/Jnc.14324 |
0.371 |
|
| 2018 |
Leussink VI, Reifenberger J, Hartung H. Case of alopecia universalis associated with alemtuzumab treatment in MS Neurology - Neuroimmunology Neuroinflammation. 5: e454. DOI: 10.1212/Nxi.0000000000000454 |
0.361 |
|
| 2018 |
McCombe P, Boyko AN, DeSeze J, Hartung H, Havrdova E, Inshasi JS, Montalban X, Pozzilli C, Selmaj KW, Vermersch P, Melanson M, Daizadeh N, Rodriguez CE, Wijmeersch BV, Investigators T. 044 Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study) Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Anzan.43 |
0.349 |
|
| 2017 |
Graf J, Leussink VI, Dehmel T, Ringelstein M, Goebels N, Adams O, MacKenzie CR, Warnke C, Feldt T, Lammerskitten A, Klotz L, Meuth S, Wiendl H, Hartung HP, Aktas O, et al. Infectious risk stratification in multiple sclerosis patients receiving immunotherapy. Annals of Clinical and Translational Neurology. 4: 909-914. PMID 29296620 DOI: 10.1002/Acn3.491 |
0.303 |
|
| 2017 |
van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Neurology. PMID 29122523 DOI: 10.1016/S1474-4422(17)30378-2 |
0.323 |
|
| 2017 |
Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology. PMID 28835403 DOI: 10.1212/Wnl.0000000000004354 |
0.316 |
|
| 2017 |
Ehler J, Blechinger S, Rommer PS, Koball S, Mitzner S, Hartung HP, Leutmezer F, Sauer M, Zettl UK. Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients-A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness. International Journal of Molecular Sciences. 18. PMID 28800066 DOI: 10.3390/Ijms18081749 |
0.364 |
|
| 2017 |
Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A. Sodium intake and multiple sclerosis activity and progression in BENEFIT. Annals of Neurology. PMID 28556498 DOI: 10.1002/Ana.24965 |
0.339 |
|
| 2017 |
Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, ... ... Hartung HP, et al. Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. Plos One. 12: e0170395. PMID 28170401 DOI: 10.1371/Journal.Pone.0170395 |
0.307 |
|
| 2016 |
Havla J, Warnke C, Derfuss T, Kappos L, Hartung HP, Hohlfeld R. Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. Deutsches Arzteblatt International. 113: 879-886. PMID 28130920 DOI: 10.3238/Arztebl.2016.0879 |
0.368 |
|
| 2016 |
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. The New England Journal of Medicine. PMID 28002688 DOI: 10.1056/Nejmoa1606468 |
0.343 |
|
| 2016 |
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. The New England Journal of Medicine. PMID 28002679 DOI: 10.1056/Nejmoa1601277 |
0.305 |
|
| 2016 |
Winter M, Baksmeier C, Steckel J, Barman S, Malviya M, Harrer-Kuster M, Hartung HP, Goebels N. Dose-dependent inhibition of demyelination and microglia activation by IVIG. Annals of Clinical and Translational Neurology. 3: 828-843. PMID 27844029 DOI: 10.1002/Acn3.326 |
0.354 |
|
| 2016 |
Meyer Zu Horste G, Cordes S, Pfaff J, Mathys C, Mausberg AK, Bendszus M, Pham M, Hartung HP, Kieseier BC. Predicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic Neuritis. Plos One. 11: e0164099. PMID 27711247 DOI: 10.1371/Journal.Pone.0164099 |
0.323 |
|
| 2016 |
Schneider R, Koop B, Schröter F, Cline J, Ingwersen J, Berndt C, Hartung HP, Aktas O, Prozorovski T. Activation of Wnt signaling promotes hippocampal neurogenesis in experimental autoimmune encephalomyelitis. Molecular Neurodegeneration. 11: 53. PMID 27480121 DOI: 10.1186/S13024-016-0117-0 |
0.337 |
|
| 2016 |
van Schaik IN, van Geloven N, Bril V, Hartung HP, Lewis RA, Sobue G, Lawo JP, Mielke O, Cornblath DR, Merkies IS. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. Trials. 17: 345. PMID 27455854 DOI: 10.1186/S13063-016-1466-2 |
0.312 |
|
| 2016 |
Lepka K, Berndt C, Hartung HP, Aktas O. Redox Events As Modulators of Pathology and Therapy of Neuroinflammatory Diseases. Frontiers in Cell and Developmental Biology. 4: 63. PMID 27446915 DOI: 10.3389/Fcell.2016.00063 |
0.352 |
|
| 2016 |
Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab. Bmc Neurology. 16: 98. PMID 27405225 DOI: 10.1186/S12883-016-0625-0 |
0.304 |
|
| 2016 |
Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P, Montalban X, Ziemssen T, Hunter B, Arnould S, Wallström E, Selmaj K. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. Jama Neurology. PMID 27380540 DOI: 10.1001/Jamaneurol.2016.1451 |
0.306 |
|
| 2016 |
Leussink VI, Hartung HP, Kieseier BC, Stettner M. Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies. Therapeutic Advances in Neurological Disorders. 9: 336-43. PMID 27366241 DOI: 10.1177/1756285616641583 |
0.354 |
|
| 2016 |
Szepanowski F, Derksen A, Steiner I, Meyer Zu Hörste G, Daldrup T, Hartung HP, Kieseier BC. Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling. Journal of Neuroinflammation. 13: 143. PMID 27283020 DOI: 10.1186/S12974-016-0612-9 |
0.314 |
|
| 2016 |
Buerth C, Mausberg AK, Heininger MK, Hartung HP, Kieseier BC, Ernst JF. Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with Candida utilis Expressing the Immunogenic MOG35-55 Peptide. Plos One. 11: e0155082. PMID 27159446 DOI: 10.1371/Journal.Pone.0155082 |
0.359 |
|
| 2016 |
Cree BA, Hartung HP. Steering through complexity: management approaches in multiple sclerosis. Current Opinion in Neurology. PMID 27058222 DOI: 10.1097/Wco.0000000000000332 |
0.319 |
|
| 2016 |
Aktas O, Albrecht P, Hartung HP. Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives. Current Opinion in Neurology. PMID 27035900 DOI: 10.1097/Wco.0000000000000327 |
0.352 |
|
| 2016 |
Jadasz JJ, Lubetzki C, Zalc B, Stankoff B, Hartung HP, Küry P. Recent achievements in stem cell-mediated myelin repair. Current Opinion in Neurology. PMID 27035898 DOI: 10.1097/Wco.0000000000000323 |
0.317 |
|
| 2016 |
Stankoff B, Jadasz JJ, Hartung HP, Küry P, Zalc B, Lubetzki C. Repair strategies for multiple sclerosis: challenges, achievements and perspectives. Current Opinion in Neurology. PMID 27035897 DOI: 10.1097/Wco.0000000000000325 |
0.359 |
|
| 2016 |
Leussink VI, Stettner M, Warnke C, Hartung HP. Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system. Journal of the Peripheral Nervous System : Jpns. PMID 26968589 DOI: 10.1111/Jns.12169 |
0.343 |
|
| 2016 |
Kremer D, Göttle P, Hartung HP, Küry P. Pushing Forward: Remyelination as the New Frontier in CNS Diseases. Trends in Neurosciences. PMID 26964504 DOI: 10.1016/J.Tins.2016.02.004 |
0.318 |
|
| 2016 |
Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. Nature Reviews. Neurology. PMID 26943779 DOI: 10.1038/Nrneurol.2016.21 |
0.34 |
|
| 2016 |
Stettner M, Hinrichs L, Guthoff R, Bairov S, Petropoulos IN, Warnke C, Hartung HP, Malik RA, Kieseier BC. Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy. Annals of Clinical and Translational Neurology. 3: 88-100. PMID 26900579 DOI: 10.1002/Acn3.275 |
0.312 |
|
| 2016 |
Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet (London, England). PMID 26827074 DOI: 10.1016/S0140-6736(15)01314-8 |
0.36 |
|
| 2016 |
Kremer D, Cui QL, Göttle P, Kuhlmann T, Hartung HP, Antel J, Küry P. CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation. Plos One. 11: e0146503. PMID 26741980 DOI: 10.1371/Journal.Pone.0146503 |
0.349 |
|
| 2016 |
Ingwersen J, Aktas O, Hartung HP. Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 13: 47-57. PMID 26701666 DOI: 10.1007/S13311-015-0412-4 |
0.346 |
|
| 2016 |
Coles A, Arnold D, Barkhof F, Filippi M, Hartung H, Havrdova E, Selmaj K, Margolin D, Thangavelu K, Schippling S, Investigators CI. Alemtuzumab Persistently Slows Brain Volume Loss In Rrms Journal of Neurology, Neurosurgery, and Psychiatry. 87. DOI: 10.1136/Jnnp-2016-315106.125 |
0.308 |
|
| 2015 |
Warnke C, Olsson T, Hartung HP. PML: The Dark Side of Immunotherapy in Multiple Sclerosis. Trends in Pharmacological Sciences. 36: 799-801. PMID 26497099 DOI: 10.1016/J.Tips.2015.09.006 |
0.389 |
|
| 2015 |
Lill CM, Luessi F, Alcina A, Sokolova EA, Ugidos N, de la Hera B, Guillot-Noël L, Malhotra S, Reinthaler E, Schjeide BM, Mescheriakova JY, Mashychev A, Wohlers I, Akkad DA, Aktas O, ... ... Hartung HP, et al. Genome-wide significant association with seven novel multiple sclerosis risk loci. Journal of Medical Genetics. PMID 26475045 DOI: 10.1136/Jmedgenet-2015-103442 |
0.327 |
|
| 2015 |
Munger KL, Fitzgerald KC, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Suarez G, Radue EW, Sandbrink R, Kappos L, Pohl C, Ascherio A. No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. Neurology. 85: 1694-701. PMID 26453645 DOI: 10.1212/Wnl.0000000000002099 |
0.355 |
|
| 2015 |
Ringelstein M, Albrecht P, Kleffner I, Bühn B, Harmel J, Müller AK, Finis D, Guthoff R, Bergholz R, Duning T, Krämer M, Paul F, Brandt A, Oberwahrenbrock T, Mikolajczak J, ... ... Hartung HP, et al. Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. Neurology. 85: 610-8. PMID 26203089 DOI: 10.1212/Wnl.0000000000001852 |
0.306 |
|
| 2015 |
Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, et al. A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up. Journal of Neuroimmunology. 285: 68-70. PMID 26198921 DOI: 10.1016/J.Jneuroim.2015.05.019 |
0.375 |
|
| 2015 |
Tzekova N, Heinen A, Bunk S, Hermann C, Hartung HP, Reipert B, Küry P. Immunoglobulins stimulate cultured Schwann cell maturation and promote their potential to induce axonal outgrowth. Journal of Neuroinflammation. 12: 107. PMID 26022648 DOI: 10.1186/S12974-015-0331-7 |
0.335 |
|
| 2015 |
Bayry J, Hartung HP, Kaveri SV. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties. Trends in Pharmacological Sciences. 36: 419-21. PMID 26003802 DOI: 10.1016/J.Tips.2015.04.012 |
0.38 |
|
| 2015 |
Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stögbauer F, Hellwig K, Ellrichmann G, Stettner M, Chan A, Hartung HP, Kieseier B, Gold R, Aktas O, Kleiter I. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. Jama Neurology. 72: 756-63. PMID 25985228 DOI: 10.1001/Jamaneurol.2015.0533 |
0.314 |
|
| 2015 |
Heinen A, Beyer F, Tzekova N, Hartung HP, Küry P. Fingolimod induces the transition to a nerve regeneration promoting Schwann cell phenotype. Experimental Neurology. 271: 25-35. PMID 25957629 DOI: 10.1016/J.Expneurol.2015.05.002 |
0.312 |
|
| 2015 |
Göttle P, Sabo JK, Heinen A, Venables G, Torres K, Tzekova N, Parras CM, Kremer D, Hartung HP, Cate HS, Küry P. Oligodendroglial maturation is dependent on intracellular protein shuttling. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 906-19. PMID 25609610 DOI: 10.1523/Jneurosci.1423-14.2015 |
0.342 |
|
| 2015 |
Kremer D, Förster M, Schichel T, Göttle P, Hartung HP, Perron H, Küry P. The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 1200-3. PMID 25480862 DOI: 10.1177/1352458514560926 |
0.333 |
|
| 2015 |
Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg AK, von Geldern G, Gold R, Kümpfel T, Hohlfeld R, Mäurer M, Stangel M, Straeten V, Limmroth V, Weber T, Kleinschnitz C, ... ... Hartung HP, et al. Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 1036-44. PMID 25392339 DOI: 10.1177/1352458514556296 |
0.349 |
|
| 2015 |
Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, et al. A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 885-93. PMID 25392325 DOI: 10.1177/1352458514554052 |
0.382 |
|
| 2015 |
Kaufman M, Cree BA, De Sèze J, Fox RJ, Gold R, Hartung HP, Jeffery D, Kappos L, Montalbán X, Weinstock-Guttman B, Ticho B, Duda P, Pace A, Campagnolo D. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. Journal of Neurology. 262: 326-36. PMID 25381458 DOI: 10.1007/S00415-014-7558-6 |
0.323 |
|
| 2015 |
Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 22-34. PMID 25344374 DOI: 10.1177/1352458514549398 |
0.368 |
|
| 2015 |
Sharrack B, Mayer L, Coles A, Hartung H, Havrdova E, Selmaj K, Margolin D, Compston A. MANAGEMENT OF ADVERSE REACTIONS TO ALEMTUZUMAB INFUSION Journal of Neurology, Neurosurgery & Psychiatry. 86: e4.23-e4. DOI: 10.1136/Jnnp-2015-312379.119 |
0.333 |
|
| 2014 |
Harmel J, Ringelstein M, Ingwersen J, Mathys C, Goebels N, Hartung HP, Jarius S, Aktas O. Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. Bmc Neurology. 14: 247. PMID 25516429 DOI: 10.1186/S12883-014-0247-3 |
0.392 |
|
| 2014 |
Meyer zu Hörste G, Cordes S, Mausberg AK, Zozulya AL, Wessig C, Sparwasser T, Mathys C, Wiendl H, Hartung HP, Kieseier BC. FoxP3+ regulatory T cells determine disease severity in rodent models of inflammatory neuropathies. Plos One. 9: e108756. PMID 25286182 DOI: 10.1371/Journal.Pone.0108756 |
0.37 |
|
| 2014 |
Meyer zu Horste G, Mausberg AK, Cordes S, El-Haddad H, Partke HJ, Leussink VI, Roden M, Martin S, Steinman L, Hartung HP, Kieseier BC. Thymic epithelium determines a spontaneous chronic neuritis in Icam1(tm1Jcgr)NOD mice. Journal of Immunology (Baltimore, Md. : 1950). 193: 2678-90. PMID 25108020 DOI: 10.4049/Jimmunol.1400367 |
0.313 |
|
| 2014 |
Ritter C, Förster D, Albrecht P, Hartung HP, Kieseier BC, Lehmann HC. IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Journal of Neuroimmunology. 274: 225-9. PMID 25002077 DOI: 10.1016/J.Jneuroim.2014.06.007 |
0.338 |
|
| 2014 |
Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, Pawlita M, Kümpfel T, Mäurer M, Stangel M, Wegner F, Hohlfeld R, Straeten V, Limmroth V, Weber T, ... ... Hartung HP, et al. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Annals of Neurology. 76: 792-801. PMID 24729444 DOI: 10.1002/Ana.24153 |
0.303 |
|
| 2014 |
Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 82: 1491-8. PMID 24682966 DOI: 10.1212/Wnl.0000000000000355 |
0.357 |
|
| 2014 |
Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet. Neurology. 13: 353-63. PMID 24613349 DOI: 10.1016/S1474-4422(14)70028-6 |
0.338 |
|
| 2014 |
Hartung HP, Aktas O, Menge T, Kieseier BC. Immune regulation of multiple sclerosis. Handbook of Clinical Neurology. 122: 3-14. PMID 24507511 DOI: 10.1016/B978-0-444-52001-2.00001-7 |
0.405 |
|
| 2014 |
Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. Jama Neurology. 71: 306-14. PMID 24445558 DOI: 10.1001/Jamaneurol.2013.5993 |
0.342 |
|
| 2014 |
Curtin F, Hartung HP. Novel therapeutic options for multiple sclerosis. Expert Review of Clinical Pharmacology. 7: 91-104. PMID 24325127 DOI: 10.1586/17512433.2014.865517 |
0.384 |
|
| 2014 |
Nagtegaal GJ, Pohl C, Wattjes MP, Hulst HE, Freedman MS, Hartung HP, Miller D, Montalban X, Kappos L, Edan G, Pleimes D, Beckman K, Stemper B, Polman CH, Sandbrink R, et al. Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 234-42. PMID 23842212 DOI: 10.1177/1352458513494491 |
0.343 |
|
| 2014 |
Dehmel T, Warnke C, Ramanujam R, Wolffram K, Leussink VI, Hartung H, Kieseier BC. Correlation of fingolimod induced lymphopenia and physical measures in MS patients Journal of Neuroimmunology. 275: 216-217. DOI: 10.1016/J.Jneuroim.2014.08.581 |
0.312 |
|
| 2014 |
Malviya M, Melzer N, Widman G, Elger C, Wiendl H, Hartung H, Goebels N. Autoimmune encephalitis: Single cell PCR analysis of the intrathecal plasma cell repertoire Journal of Neuroimmunology. 275: 5. DOI: 10.1016/J.Jneuroim.2014.08.019 |
0.312 |
|
| 2013 |
Warnke C, Mausberg AK, Stettner M, Dehmel T, Nekrich L, Meyer zu Horste G, Hartung HP, Fogdell-Hahn A, Adams O, Kieseier BC. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology. 81: 1400-8. PMID 24049136 DOI: 10.1212/Wnl.0B013E3182A84101 |
0.394 |
|
| 2013 |
Lehmann HC, Hughes RA, Hartung HP. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Handbook of Clinical Neurology. 115: 415-27. PMID 23931793 DOI: 10.1016/B978-0-444-52902-2.00023-0 |
0.357 |
|
| 2013 |
Pfeifenbring S, Metz I, Kremer D, Küry P, Hartung HP, Brück W. Oligodendroglial lineage cells express nuclear p57kip2 in multiple sclerosis lesions. Glia. 61: 1250-60. PMID 23828667 DOI: 10.1002/Glia.22512 |
0.363 |
|
| 2013 |
Warnke C, Kieseier BC, Hartung HP. Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards. Journal of Neural Transmission (Vienna, Austria : 1996). 120: S55-60. PMID 23793997 DOI: 10.1007/S00702-013-1055-4 |
0.375 |
|
| 2013 |
Buttmann M, Kaveri S, Hartung HP. Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. Trends in Pharmacological Sciences. 34: 445-57. PMID 23791035 DOI: 10.1016/J.Tips.2013.05.009 |
0.393 |
|
| 2013 |
Stettner M, Wolffram K, Mausberg AK, Albrecht P, Derksen A, Methner A, Dehmel T, Hartung HP, Dietrich H, Kieseier BC. Promoting myelination in an in vitro mouse model of the peripheral nervous system: the effect of wine ingredients [corrected]. Plos One. 8: e66079. PMID 23762469 DOI: 10.1371/Journal.Pone.0066079 |
0.308 |
|
| 2013 |
Warnke C, Pawlita M, Dehmel T, Posevitz-Fejfar A, Hartung HP, Wiendl H, Kieseier BC, Adams O. An assay to quantify species-specific anti-JC virus antibody levels in MS patients. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 1137-44. PMID 23388163 DOI: 10.1177/1352458513475489 |
0.305 |
|
| 2013 |
Jantzen SU, Ferrea S, Wach C, Quasthoff K, Illes S, Scherfeld D, Hartung HP, Seitz RJ, Dihné M. In vitro neuronal network activity in NMDA receptor encephalitis. Bmc Neuroscience. 14: 17. PMID 23379293 DOI: 10.1186/1471-2202-14-17 |
0.5 |
|
| 2013 |
Lill CM, Schjeide BM, Graetz C, Liu T, Damotte V, Akkad DA, Blaschke P, Gerdes LA, Kroner A, Luessi F, Cournu-Rebeix I, Hoffjan S, Winkelmann A, Touze E, Pico F, ... ... Hartung HP, et al. Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk. Journal of Medical Genetics. 50: 140-3. PMID 23315543 DOI: 10.1136/Jmedgenet-2012-101411 |
0.332 |
|
| 2013 |
Comi G, Hartung HP, Kurukulasuriya NC, Greenberg SJ, Scaramozza M. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Expert Opinion On Pharmacotherapy. 14: 123-36. PMID 23256518 DOI: 10.1517/14656566.2013.754012 |
0.395 |
|
| 2013 |
Lee JI, Macht S, Albrecht P, Hartung HP, Goebels N. Brachial amyotrophic diparesis associated with anti-Hu positive anterior horn cell disease and autonomic disorder. Journal of Neurology. 260: 301-2. PMID 23135291 DOI: 10.1007/S00415-012-6711-3 |
0.319 |
|
| 2012 |
Lehmann HC, Hughes RA, Kieseier BC, Hartung HP. Recent developments and future directions in Guillain-Barré syndrome. Journal of the Peripheral Nervous System : Jpns. 17: 57-70. PMID 23279434 DOI: 10.1111/J.1529-8027.2012.00433.X |
0.325 |
|
| 2012 |
Curtin F, Lang AB, Perron H, Laumonier M, Vidal V, Porchet HC, Hartung HP. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study. Clinical Therapeutics. 34: 2268-78. PMID 23200102 DOI: 10.1016/J.Clinthera.2012.11.006 |
0.319 |
|
| 2012 |
Jander S, Turowski B, Kieseier BC, Hartung H. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Multiple Sclerosis Journal. 18: 1650-1652. PMID 23100527 DOI: 10.1177/1352458512463768 |
0.326 |
|
| 2012 |
Mentzer D, Prestel J, Adams O, Gold R, Hartung HP, Hengel H, Kieseier BC, Ludwig WD, Keller-Stanislawski B. Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. Journal of Neurology, Neurosurgery, and Psychiatry. 83: 927-33. PMID 22807558 DOI: 10.1136/Jnnp-2012-302478 |
0.31 |
|
| 2012 |
Köhne A, Stettner M, Jangouk P, Dehmel T, Hartung HP, Lehmann HC, Kieseier BC. Fingolimod impedes Schwann cell-mediated myelination: implications for the treatment of immune neuropathies? Archives of Neurology. 69: 1280-9. PMID 22751954 DOI: 10.1001/Archneurol.2012.394 |
0.364 |
|
| 2012 |
Warnke C, Dehmel T, Posevitz-Fejfár A, Chan A, Berthele A, Schmidt S, Haas J, Kronsbein HC, Seitz F, Tackenberg B, Mäurer M, Gerbershagen K, Limmroth V, Adams O, Hartung HP, et al. Anti-JC-virus antibody prevalence in a German MS cohort. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 1054-5. PMID 22740609 DOI: 10.1177/1352458511429955 |
0.302 |
|
| 2012 |
Caloyeras JP, Zhang B, Wang C, Eriksson M, Fredrikson S, Beckmann K, Knappertz V, Pohl C, Hartung HP, Shah D, Miller JD, Sandbrink R, Lanius V, Gondek K, Russell MW. Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis. Clinical Therapeutics. 34: 1132-44. PMID 22541587 DOI: 10.1016/J.Clinthera.2012.03.004 |
0.345 |
|
| 2012 |
Penner IK, Stemper B, Calabrese P, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Pleimes D, Lanius V, Pohl C, Kappos L, Sandbrink R. Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 1466-71. PMID 22492127 DOI: 10.1177/1352458512442438 |
0.31 |
|
| 2012 |
Husseini L, Saleh A, Reifenberger G, Hartung HP, Kieseier BC. Inflammatory demyelinating brain lesions heralding primary CNS lymphoma. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 39: 6-10. PMID 22384490 DOI: 10.1017/S0317167100012610 |
0.311 |
|
| 2012 |
Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O. Failure of natalizumab to prevent relapses in neuromyelitis optica Archives of Neurology. 69: 239-245. PMID 22332191 DOI: 10.1001/Archneurol.2011.216 |
0.367 |
|
| 2012 |
Rieckmann P, Heidenreich F, Sailer M, Zettl UK, Zessack N, Hartung HP, Gold R. Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Therapeutic Advances in Neurological Disorders. 5: 3-12. PMID 22276072 DOI: 10.1177/1756285611428503 |
0.344 |
|
| 2012 |
Loebermann M, Winkelmann A, Hartung HP, Hengel H, Reisinger EC, Zettl UK. Vaccination against infection in patients with multiple sclerosis Nature Reviews Neurology. 8: 143-151. PMID 22270022 DOI: 10.1038/Nrneurol.2012.8 |
0.328 |
|
| 2012 |
Lill CM, Schjeide BM, Akkad DA, Blaschke P, Winkelmann A, Gerdes LA, Hoffjan S, Luessi F, Dörner T, Li SC, Steinhagen-Thiessen E, Lindenberger U, Chan A, Hartung HP, Aktas O, et al. Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sample. Neurogenetics. 13: 83-6. PMID 22095036 DOI: 10.1007/S10048-011-0305-6 |
0.312 |
|
| 2012 |
Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP. Cladribine as a therapeutic option in multiple sclerosis Clinical Immunology. 142: 68-75. PMID 21733757 DOI: 10.1016/J.Clim.2011.05.009 |
0.325 |
|
| 2012 |
Ingwersen J, Aktas O, Kuery P, Kieseier B, Boyko A, Hartung HP. Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy Clinical Immunology. 142: 15-24. PMID 21669553 DOI: 10.1016/J.Clim.2011.05.005 |
0.382 |
|
| 2012 |
Bril V, Cornblath DR, Hartung H, Lewis RA, Merkies IS, Zenker O, Bexon M, Schaik INv. PATH (polyneuropathy and treatment with Hizentra ®: a randomized, controlled trial of Hizentra ®, a 20% immunoglobulin preparation for subcutaneous administration, in patients with chronic inflammatory demyelinating polyradiculoneuropathy F1000research. 3. DOI: 10.7490/F1000Research.1090020.1 |
0.315 |
|
| 2012 |
Brandt AU, Zimmermann H, Kaufhold F, Promesberger J, Schippling S, Finis D, Aktas O, Geis C, Ringelstein M, Ringelstein EB, Hartung HP, Paul F, Kleffner I, Dörr J. Patterns of retinal damage facilitate differential diagnosis between Susac syndrome and MS Plos One. 7. DOI: 10.1371/Journal.Pone.0038741 |
0.338 |
|
| 2011 |
Hecker M, Paap BK, Goertsches RH, Kandulski O, Fatum C, Koczan D, Hartung HP, Thiesen HJ, Zettl UK. Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis. Plos One. 6: e29648. PMID 22216338 DOI: 10.1371/Journal.Pone.0029648 |
0.334 |
|
| 2011 |
Dihné M, Hartung HP, Seitz RJ. Restoring neuronal function after stroke by cell replacement: anatomic and functional considerations. Stroke; a Journal of Cerebral Circulation. 42: 2342-50. PMID 21737804 DOI: 10.1161/Strokeaha.111.613422 |
0.47 |
|
| 2011 |
Hartung HP, Lehmann HC, Kieseier BC, Hughes RA. Novel treatment for immune neuropathies on the horizon. Journal of the Peripheral Nervous System : Jpns. 16: 75-83. PMID 21692904 DOI: 10.1111/J.1529-8027.2011.00334.X |
0.36 |
|
| 2011 |
Kremer D, Aktas O, Hartung HP, Küry P. The complex world of oligodendroglial differentiation inhibitors Annals of Neurology. 69: 602-618. PMID 21520230 DOI: 10.1002/Ana.22415 |
0.383 |
|
| 2011 |
Kotter MR, Stadelmann C, Hartung HP. Enhancing remyelination in disease--can we wrap it up? Brain : a Journal of Neurology. 134: 1882-900. PMID 21507994 DOI: 10.1093/Brain/Awr014 |
0.37 |
|
| 2011 |
Matzke B, Metze C, Winkelmann A, Grossmann A, Hartung HP, Benecke R, Zettl UK. Severe relapse of multiple sclerosis during plasma exchange treatment. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 759-62. PMID 21427132 DOI: 10.1177/1352458511401461 |
0.315 |
|
| 2011 |
Hartung HP, Aktas O. Evolution of multiple sclerosis treatment: Next generation therapies meet next generation efficacy criteria The Lancet Neurology. 10: 293-295. PMID 21397566 DOI: 10.1016/S1474-4422(11)70043-6 |
0.315 |
|
| 2011 |
Hartung H, Montalban X, Sorensen PS, Vermersch P, Olsson T. Principles of a new treatment algorithm in multiple sclerosis. Expert Review of Neurotherapeutics. 11: 351-362. PMID 21375441 DOI: 10.1586/Ern.11.15 |
0.355 |
|
| 2011 |
Menge T, Hartung HP, Kieseier BC. Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now : Commentary to: 10.1007/s00415-010-5844-5 "One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients" by S. Malucchi et al. Journal of Neurology. 258: 904-7. PMID 21340521 DOI: 10.1007/S00415-011-5941-0 |
0.394 |
|
| 2011 |
Lehmann HC, Hartung HP. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. Journal of Neuroimmunology. 231: 61-9. PMID 21056913 DOI: 10.1016/J.Jneuroim.2010.09.015 |
0.35 |
|
| 2011 |
Aktas O, Hartung H. Oral therapies for multiple sclerosis: fingolimod and cladribine Hot Topics in Neurology and Psychiatry. DOI: 10.4147/Htn-100929 |
0.316 |
|
| 2010 |
Hartung H, Kieseier BC. Atacicept: targeting B cells in multiple sclerosis. Therapeutic Advances in Neurological Disorders. 3: 205-216. PMID 21179612 DOI: 10.1177/1756285610371146 |
0.352 |
|
| 2010 |
Warnke C, Smolianov V, Dehmel T, Andrée M, Hengel H, Zohren F, Arendt G, Wiendl H, Haas R, Hartung HP, Adams O, Kieseier BC. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 151-6. PMID 21078695 DOI: 10.1177/1352458510385834 |
0.338 |
|
| 2010 |
Sominanda A, Lundkvist M, Fogdell-Hahn A, Hemmer B, Hartung HP, Hillert J, Menge T, Kieseier BC. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta. Archives of Neurology. 67: 1095-101. PMID 20837854 DOI: 10.1001/Archneurol.2010.218 |
0.306 |
|
| 2010 |
Donofrio PD, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Hughes R, Latov N, Merkies I, van Doorn P. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Archives of Neurology. 67: 1082-8. PMID 20837852 DOI: 10.1001/Archneurol.2010.223 |
0.326 |
|
| 2010 |
Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, Stüve O. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Archives of Neurology. 67: 923-30. PMID 20697042 DOI: 10.1001/Archneurol.2010.161 |
0.389 |
|
| 2010 |
Wolf C, Menge T, Stenner MP, Meyer zu Hörste G, Saleh A, Hartung HP, Wiendl H, Kieseier BC. Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Archives of Neurology. 67: 881-3. PMID 20625098 DOI: 10.1001/Archneurol.2010.143 |
0.358 |
|
| 2010 |
Mix E, Meyer-Rienecker H, Hartung H, Zettl UK. Animal models of multiple sclerosis--potentials and limitations. Progress in Neurobiology. 92: 386-404. PMID 20558237 DOI: 10.1016/J.Pneurobio.2010.06.005 |
0.382 |
|
| 2010 |
Aktas O, Küry P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis Nature Reviews Neurology. 6: 373-382. PMID 20551946 DOI: 10.1038/Nrneurol.2010.76 |
0.358 |
|
| 2010 |
Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, Hanna K, Hartung HP, Hughes RA, Merkies IS, van Doorn PA. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Archives of Neurology. 67: 802-7. PMID 20457948 DOI: 10.1001/Archneurol.2010.105 |
0.3 |
|
| 2010 |
Hartung HP, Aktas O. Oral therapies for multiple sclerosis: are we there yet? The Lancet Neurology. 9: 454-457. PMID 20398852 DOI: 10.1016/S1474-4422(10)70088-0 |
0.314 |
|
| 2010 |
Aktas O, Kieseier B, Hartung HP. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends in Neurosciences. 33: 140-52. PMID 20045200 DOI: 10.1016/J.Tins.2009.12.002 |
0.402 |
|
| 2010 |
Aktas O, Hartung HP. Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases. Journal of Neurology. 256: 1906-8. PMID 19768482 DOI: 10.1007/S00415-009-5317-X |
0.407 |
|
| 2010 |
Meyer Zu Horste G, Heidenreich H, Lehmann HC, Ferrone S, Hartung HP, Wiendl H, Kieseier BC. Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies. Glia. 58: 80-92. PMID 19544394 DOI: 10.1002/Glia.20903 |
0.32 |
|
| 2009 |
Lehmann HC, Meyer Zu Horste G, Kieseier BC, Hartung HP. Pathogenesis and treatment of immune-mediated neuropathies. Therapeutic Advances in Neurological Disorders. 2: 261-81. PMID 21179533 DOI: 10.1177/1756285609104792 |
0.327 |
|
| 2009 |
Hartung HP, Aktas O. Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope. Annals of Neurology. 66: 429-32. PMID 19847907 DOI: 10.1002/Ana.21880 |
0.323 |
|
| 2009 |
Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. The Lancet. Neurology. 8: 987-97. PMID 19748319 DOI: 10.1016/S1474-4422(09)70237-6 |
0.333 |
|
| 2009 |
Cepok S, Schreiber H, Hoffmann S, Zhou D, Neuhaus O, von Geldern G, Hochgesand S, Nessler S, Rothhammer V, Lang M, Hartung HP, Hemmer B. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Archives of Neurology. 66: 1216-23. PMID 19667211 DOI: 10.1001/Archneurol.2009.138 |
0.327 |
|
| 2009 |
Lehmann HC, Hartung HP. Variants of Guillain-Barré syndrome: low incidence but high impact. Journal of Neurology. 256: 1909-10. PMID 19633905 DOI: 10.1007/S00415-009-5253-9 |
0.323 |
|
| 2009 |
Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, Zettl UK. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiology of Disease. 35: 117-27. PMID 19426803 DOI: 10.1016/J.Nbd.2009.04.010 |
0.354 |
|
| 2009 |
Hartung HP. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Expert Opinion On Pharmacotherapy. 10: 291-309. PMID 19236200 DOI: 10.1517/14656560802677882 |
0.357 |
|
| 2009 |
Stüve O, Leussink VI, Fröhlich R, Hemmer B, Hartung HP, Menge T, Kieseier BC. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Archives of Neurology. 66: 259-61. PMID 19204165 DOI: 10.1001/Archneurol.2008.551 |
0.332 |
|
| 2009 |
Wellen J, Walter J, Jangouk P, Hartung HP, Dihné M. Neural precursor cells as a novel target for interferon-beta. Neuropharmacology. 56: 386-98. PMID 18930745 DOI: 10.1016/J.Neuropharm.2008.09.011 |
0.312 |
|
| 2009 |
Vollmar P, Nessler S, Kalluri SR, Hartung HP, Hemmer B. The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 12: 525-36. PMID 18922202 DOI: 10.1017/S1461145708009425 |
0.352 |
|
| 2009 |
Hartung H. New oral therapies may offer improved treatment options for patients with multiple sclerosis Current Opinion in Neurology. 22: S10-S14. DOI: 10.1097/01.Wco.0000347402.08903.87 |
0.359 |
|
| 2008 |
König FB, Wildemann B, Nessler S, Zhou D, Hemmer B, Metz I, Hartung HP, Kieseier BC, Brück W. Persistence of immunopathological and radiological traits in multiple sclerosis. Archives of Neurology. 65: 1527-32. PMID 19001173 DOI: 10.1001/Archneur.65.11.1527 |
0.387 |
|
| 2008 |
Kieseier BC, Meyer Zu Hörste G, Lehmann HC, Gold R, Hartung HP. Intravenous immunoglobulins in the treatment of immune neuropathies. Current Opinion in Neurology. 21: 555-62. PMID 18769249 DOI: 10.1097/Wco.0B013E32830Efc03 |
0.31 |
|
| 2008 |
Hartung HP, Kieseier BC. Advances in biotechnology and novel insights into pathophysiology have contributed to an increased understanding of the pathomechanisms of diseases affecting the peripheral nervous system. Current Opinion in Neurology. 21: 517-8. PMID 18769243 DOI: 10.1097/Wco.0B013E32830F1E61 |
0.301 |
|
| 2008 |
Jörgens S, Biermann-Ruben K, Kurz MW, Flügel C, Daehli Kurz K, Antke C, Hartung HP, Seitz RJ, Schnitzler A. Word deafness as a cortical auditory processing deficit: a case report with MEG. Neurocase. 14: 307-16. PMID 18766983 DOI: 10.1080/13554790802363738 |
0.475 |
|
| 2008 |
Hartung H. Advances in the understanding of the mechanism of action of IVIg. Journal of Neurology. 255: 3-6. PMID 18685919 DOI: 10.1007/S00415-008-3002-0 |
0.33 |
|
| 2008 |
Killestein J, Hartung HP. Interferon beta in multiple sclerosis: predicting response at an early stage. Journal of Neurology, Neurosurgery, and Psychiatry. 79: 616-7. PMID 18487553 DOI: 10.1136/Jnnp.2007.138396 |
0.391 |
|
| 2008 |
Zohren F, Toutzaris D, Klärner V, Hartung H, Kieseier B, Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34 hematopoietic progenitor cells in humans Blood. 111: 3893-3895. PMID 18235044 DOI: 10.1182/Blood-2007-10-120329 |
0.316 |
|
| 2008 |
Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Selmaj K, Uitdehaag BM, Dahms S, Bauer L, Pohl C, Sandbrink R. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. Journal of Neurology. 255: 480-7. PMID 18004635 DOI: 10.1007/S00415-007-0733-2 |
0.342 |
|
| 2008 |
Neuhaus O, Kieseier BC, Hartung HP. Immunosuppressive agents in multiple sclerosis. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 4: 654-60. PMID 17920546 DOI: 10.1016/J.Nurt.2007.08.003 |
0.364 |
|
| 2008 |
Meyer zu Hörste G, Hu W, Hartung HP, Lehmann HC, Kieseier BC. The immunocompetence of Schwann cells. Muscle & Nerve. 37: 3-13. PMID 17823955 DOI: 10.1002/Mus.20893 |
0.356 |
|
| 2007 |
Albrecht P, Fröhlich R, Hartung HP, Kieseier BC, Methner A. Optical coherence tomography measures axonal loss in multiple sclerosis independently of optic neuritis. Journal of Neurology. 254: 1595-6. PMID 17987252 DOI: 10.1007/S00415-007-0538-3 |
0.365 |
|
| 2007 |
Hemmer B, Hartung HP. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Annals of Neurology. 62: 314-26. PMID 17969020 DOI: 10.1002/Ana.21289 |
0.393 |
|
| 2007 |
Barkhof F, Polman CH, Radue EW, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Poppe P, de Vos M, Lasri F, Bauer L, Dahms S, Wagner K, et al. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Archives of Neurology. 64: 1292-8. PMID 17846268 DOI: 10.1001/Archneur.64.9.1292 |
0.311 |
|
| 2007 |
Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet (London, England). 370: 389-97. PMID 17679016 DOI: 10.1016/S0140-6736(07)61194-5 |
0.35 |
|
| 2007 |
Nessler S, Boretius S, Stadelmann C, Bittner A, Merkler D, Hartung HP, Michaelis T, Brück W, Frahm J, Sommer N, Hemmer B. Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain : a Journal of Neurology. 130: 2186-98. PMID 17617655 DOI: 10.1093/Brain/Awm105 |
0.305 |
|
| 2007 |
Kieseier BC, Wiendl H, Hemmer B, Hartung HP. Treatment and treatment trials in multiple sclerosis. Current Opinion in Neurology. 20: 286-93. PMID 17495622 DOI: 10.1097/Wco.0B013E3281568B80 |
0.323 |
|
| 2007 |
Neuhaus O, Hartung HP. Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. Expert Review of Neurotherapeutics. 7: 547-56. PMID 17492904 DOI: 10.1586/14737175.7.5.547 |
0.39 |
|
| 2007 |
Hartung H, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, et al. Neutralising antibodies to interferon β in multiple sclerosis Journal of Neurology. 254: 827-837. PMID 17457510 DOI: 10.1007/S00415-006-0486-3 |
0.345 |
|
| 2007 |
Wiendl H, Kieseier BC, Weissert R, Mylius HA, Pichlmeier U, Hartung H, Melms A, Kuker W, Weller M. Treatment of active secondary progressivemultiple sclerosis with treosulfan Journal of Neurology. 254: 884-889. PMID 17446994 DOI: 10.1007/S00415-006-0459-6 |
0.385 |
|
| 2007 |
Lehmann HC, Köhne A, Meyer zu Hörste G, Dehmel T, Kiehl O, Hartung HP, Kastenbauer S, Kieseier BC. Role of nitric oxide as mediator of nerve injury in inflammatory neuropathies. Journal of Neuropathology and Experimental Neurology. 66: 305-12. PMID 17413321 DOI: 10.1097/Nen.0B013E3180408Daa |
0.322 |
|
| 2007 |
Meyer zu Hörste G, Hartung HP, Kieseier BC. From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nature Clinical Practice. Neurology. 3: 198-211. PMID 17410107 DOI: 10.1038/Ncpneuro0452 |
0.37 |
|
| 2007 |
Neuhaus O, Kieseier BC, Hartung HP. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. Journal of the Neurological Sciences. 259: 27-37. PMID 17391705 DOI: 10.1016/J.Jns.2006.05.071 |
0.345 |
|
| 2007 |
Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R. Lack of association between antimyelin antibodies and progression to multiple sclerosis. The New England Journal of Medicine. 356: 371-8. PMID 17251533 DOI: 10.1056/Nejmoa063602 |
0.389 |
|
| 2007 |
Dehmel T, Janke A, Hartung HP, Goebel HH, Wiendl H, Kieseier BC. The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. Neurobiology of Disease. 25: 665-74. PMID 17207628 DOI: 10.1016/J.Nbd.2006.11.008 |
0.301 |
|
| 2007 |
Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP. Immunopathogenesis and immunotherapy of multiple sclerosis. Nature Clinical Practice. Neurology. 2: 201-11. PMID 16932551 DOI: 10.1038/Ncpneuro0154 |
0.405 |
|
| 2007 |
Zohren F, Czibere A, Toutzaris D, Hartung H, Bruns I, Haas R. Treatment with Natalizumab in Patients with Multiple Sclerosis Is Associated with Increased Numbers of Circulating CD34+ Cells in the Peripheral Blood. Blood. 110: 4916-4916. DOI: 10.1182/Blood.V110.11.4916.4916 |
0.302 |
|
| 2007 |
Kappos L, Montalban X, Hartung H, Freedman M, Polman C. Treating clinically isolated syndromes suggestive of MS – Authors' reply The Lancet. 370: 2000-2001. DOI: 10.1016/S0140-6736(07)61855-8 |
0.321 |
|
| 2007 |
Hemmer B, Töpfner N, Hartung H. 18 – Immunopathogenesis of Multiple Sclerosis Neurobiology of Disease. 197-204. DOI: 10.1016/B978-012088592-3/50020-7 |
0.422 |
|
| 2006 |
Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Brück W, Hartung HP, Stadelmann C, Hemmer B. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 103: 19057-62. PMID 17142321 DOI: 10.1073/Pnas.0607242103 |
0.396 |
|
| 2006 |
Kieseier BC, Hartung HP. Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis. Neurology. 66: 955; author reply 95. PMID 16567732 DOI: 10.1212/01.Wnl.0000218668.17791.Cf |
0.335 |
|
| 2006 |
Hartung HP, Kieseier BC, Hemmer B. Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. Journal of Neurology. v30-7. PMID 16254700 DOI: 10.1007/S00415-005-5006-3 |
0.392 |
|
| 2006 |
Kurz M, Pischel H, Hartung HP, Kieseier BC. Tumor necrosis factor-alpha-converting enzyme is expressed in the inflamed peripheral nervous system. Journal of the Peripheral Nervous System : Jpns. 10: 311-8. PMID 16221290 DOI: 10.1111/J.1085-9489.2005.10309.X |
0.322 |
|
| 2006 |
Neuhaus O, Kieseier BC, Hartung HP. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacology & Therapeutics. 109: 198-209. PMID 16095713 DOI: 10.1016/J.Pharmthera.2005.07.002 |
0.369 |
|
| 2005 |
Gold R, Hartung HP. Towards individualised multiple-sclerosis therapy. The Lancet. Neurology. 4: 693-4. PMID 16239174 DOI: 10.1016/S1474-4422(05)70205-2 |
0.315 |
|
| 2005 |
Hartung HP. Early treatment and dose optimisation BENEFIT and BEYOND. Journal of Neurology. iii44-iii50. PMID 16170501 DOI: 10.1007/S00415-005-2017-Z |
0.337 |
|
| 2005 |
Zickler P, Seitz RJ, Hartung HP, Hefter H. Bilateral medullary pyramid infarction. Neurology. 64: 1801. PMID 15911818 DOI: 10.1212/01.Wnl.0000148483.84261.49 |
0.492 |
|
| 2005 |
Köller H, Schroeter M, Kieseier BC, Hartung HP. Chronic inflammatory demyelinating polyneuropathy--update on pathogenesis, diagnostic criteria and therapy. Current Opinion in Neurology. 18: 273-8. PMID 15891411 DOI: 10.1097/01.Wco.0000169744.14288.D1 |
0.329 |
|
| 2005 |
Kieseier BC, Hemmer B, Hartung HP. Multiple sclerosis--novel insights and new therapeutic strategies. Current Opinion in Neurology. 18: 211-20. PMID 15891402 DOI: 10.1097/01.Wco.0000169735.60922.Fb |
0.363 |
|
| 2005 |
Menge T, Hartung HP, Stüve O. Statins--a cure-all for the brain? Nature Reviews. Neuroscience. 6: 325-31. PMID 15803163 DOI: 10.1038/Nrn1652 |
0.319 |
|
| 2005 |
Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. The New England Journal of Medicine. 352: 1343-56. PMID 15800230 DOI: 10.1056/Nejmra041347 |
0.311 |
|
| 2005 |
Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J, Sommer N, Hartung HP, Hemmer B. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain : a Journal of Neurology. 128: 1667-76. PMID 15800022 DOI: 10.1093/Brain/Awh486 |
0.384 |
|
| 2005 |
Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, Weller M, Wiendl H. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. Journal of Neuroimmunology. 159: 155-64. PMID 15652415 DOI: 10.1016/J.Jneuroim.2004.09.016 |
0.329 |
|
| 2005 |
Amato MP, Grimaud J, Achiti I, Bartolozzi ML, Adeleine P, Hartung HP, Kappos L, Thompson A, Trojano M, Vukusic S, Confavreux C. European validation of a standardized clinical description of multiple sclerosis. Journal of Neurology. 251: 1472-80. PMID 15645346 DOI: 10.1007/S00415-004-0567-0 |
0.305 |
|
| 2004 |
Neuhaus O, Kieseier BC, Hartung HP. Mitoxantrone (Novantrone) in multiple sclerosis: new insights. Expert Review of Neurotherapeutics. 4: 17-26. PMID 15853611 DOI: 10.1586/14737175.4.1.17 |
0.362 |
|
| 2004 |
Seitz RJ, Kleiser R, Bütefisch CM, Jörgens S, Neuhaus O, Hartung HP, Wittsack HJ, Sturm V, Hermann MM. Bimanual recoupling by visual cueing in callosal disconnection. Neurocase. 10: 316-25. PMID 15788269 DOI: 10.1080/13554790490505373 |
0.454 |
|
| 2004 |
Hartung H, Bar-Or A, Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS? Journal of Neurology. 251. PMID 15549350 DOI: 10.1007/S00415-004-1504-Y |
0.409 |
|
| 2004 |
Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle & Nerve. 30: 131-56. PMID 15266629 DOI: 10.1002/Mus.20076 |
0.345 |
|
| 2004 |
Hartung HP, Munschauer FE. Assessment and management of neutralizing antibodies in patients with multiple sclerosis. Journal of Neurology. II40-2. PMID 15264111 DOI: 10.1007/S00415-004-1207-4 |
0.352 |
|
| 2004 |
Billiau A, Kieseier BC, Hartung HP. Biologic role of interferon beta in multiple sclerosis. Journal of Neurology. II10-4. PMID 15264107 DOI: 10.1007/S00415-004-1203-8 |
0.313 |
|
| 2004 |
Neuhaus O, Kieseier BC, Hartung HP. Mechanisms of mitoxantrone in multiple sclerosis--what is known? Journal of the Neurological Sciences. 223: 25-7. PMID 15261556 DOI: 10.1016/J.Jns.2004.04.015 |
0.36 |
|
| 2004 |
Kieseier BC, Archelos JJ, Hartung HP. Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Archives of Neurology. 61: 929-32. PMID 15210533 DOI: 10.1001/Archneur.61.6.929 |
0.317 |
|
| 2004 |
Neuhaus O, Stüve O, Zamvil SS, Hartung HP. Are statins a treatment option for multiple sclerosis? The Lancet. Neurology. 3: 369-71. PMID 15157852 DOI: 10.1016/S1474-4422(04)00770-7 |
0.381 |
|
| 2004 |
Neuhaus O, Kieseier BC, Klimke A, Gaebel W, Hohlfeld R, Hartung HP. [Cannabinoids in multiple sclerosis. Opportunity or hazard?]. Der Nervenarzt. 75: 1022-6. PMID 15156287 DOI: 10.1007/S00115-004-1738-Z |
0.335 |
|
| 2004 |
Hu W, Mathey E, Hartung HP, Kieseier BC. Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve. Neurology. 61: 1774-9. PMID 14694045 DOI: 10.1212/01.Wnl.0000098884.75756.4D |
0.309 |
|
| 2004 |
Gold R, Kieseier BC, Hartung H. Neue Therapieansätze bei der Multiplen Sklerose Psychoneuro. 30: 375-379. DOI: 10.1055/S-2004-831081 |
0.375 |
|
| 2004 |
Zettl UK, Mix E, Hartung H. Diagnostische Kriterien der Multiplen Sklerose - Aktuelle Aspekte Psychoneuro. 30: 370-374. DOI: 10.1055/S-2004-831080 |
0.302 |
|
| 2004 |
Hartung H, Schellekens H, Munschauer FE. Neutralizing antibodies to interferon beta in patients with multiple sclerosis: scientific background and clinical implications Journal of Neurology. 251: ii1-ii3. DOI: 10.1007/S00415-004-1201-X |
0.32 |
|
| 2003 |
Schroeter M, Stoll G, Weissert R, Hartung HP, Lassmann H, Jander S. CD8+ phagocyte recruitment in rat experimental autoimmune encephalomyelitis: association with inflammatory tissue destruction. The American Journal of Pathology. 163: 1517-24. PMID 14507658 DOI: 10.1016/S0002-9440(10)63508-0 |
0.309 |
|
| 2003 |
Kieseier BC, Hartung HP. Therapeutic strategies in the Guillain-Barré syndrome. Seminars in Neurology. 23: 159-68. PMID 12894381 DOI: 10.1055/S-2003-41132 |
0.357 |
|
| 2003 |
Wiendl H, Neuhaus O, Mehling M, Wintterle S, Schreiner B, Mitsdoerffer M, Wienhold W, Weissert R, Wessels J, Hartung H, Weller M, Tolosa E, Melms A. The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis Journal of Neuroimmunology. 140: 177-187. PMID 12864987 DOI: 10.1016/S0165-5728(03)00172-3 |
0.344 |
|
| 2003 |
Kieseier BC, Hartung HP. Multiple paradigm shifts in multiple sclerosis. Current Opinion in Neurology. 16: 247-52. PMID 12858058 DOI: 10.1097/01.Wco.0000073923.19076.75 |
0.338 |
|
| 2003 |
Kieseier BC, Pischel H, Neuen-Jacob E, Tourtellotte WW, Hartung HP. ADAM-10 and ADAM-17 in the inflamed human CNS. Glia. 42: 398-405. PMID 12730960 DOI: 10.1002/Glia.10226 |
0.384 |
|
| 2003 |
Hemmer B, Kieseier B, Cepok S, Hartung HP. New immunopathologic insights into multiple sclerosis. Current Neurology and Neuroscience Reports. 3: 246-55. PMID 12691630 DOI: 10.1007/S11910-003-0085-Y |
0.391 |
|
| 2003 |
Kastenbauer S, Koedel U, Wick M, Kieseier BC, Hartung H, Pfister H. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. Journal of Neuroimmunology. 137: 210-217. PMID 12667665 DOI: 10.1016/S0165-5728(03)00085-7 |
0.33 |
|
| 2003 |
Neuhaus O, Archelos JJ, Hartung HP. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends in Pharmacological Sciences. 24: 131-8. PMID 12628358 DOI: 10.1016/S0165-6147(03)00028-2 |
0.397 |
|
| 2003 |
Enzinger C, Ropele S, Strasser-Fuchs S, Kapeller P, Schmidt H, Poltrum B, Schmidt R, Hartung HP, Fazekas F. Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. Archives of Neurology. 60: 65-70. PMID 12533090 DOI: 10.1001/Archneur.60.1.65 |
0.316 |
|
| 2003 |
Stangel M, Hartung HP. Remyelinating strategies for the treatment of multiple sclerosis. Progress in Neurobiology. 68: 361-76. PMID 12531235 DOI: 10.1016/S0301-0082(02)00105-3 |
0.378 |
|
| 2003 |
Kieseier BC, Dalakas MC, Hartung HP. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology. 59: S7-12. PMID 12499465 DOI: 10.1212/Wnl.59.12_Suppl_6.S7 |
0.365 |
|
| 2003 |
Neuhaus O, Kieseier BC, Archelos JJ, Hartung H. Response to Mousavizadeh et al.: Oxidative toxicity and glutamate excitotoxicity in multiple sclerosis Trends in Pharmacological Sciences. 24: 564-565. DOI: 10.1016/J.Tips.2003.09.005 |
0.322 |
|
| 2002 |
Hartung HP, Gonsette R, König N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T, Albrecht H, Basedow-Rajwich B, Hofmeister R, Pöllmann W, Starck M, Beer K, Hopf HC, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial Lancet. 360: 2018-2025. PMID 12504397 DOI: 10.1016/S0140-6736(02)12023-X |
0.333 |
|
| 2002 |
Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nature Reviews. Neuroscience. 3: 291-301. PMID 11967559 DOI: 10.1038/Nrn784 |
0.41 |
|
| 2001 |
Feasby TE, Hartung H. Drain the roots A new treatment for Guillain–Barré syndrome? Neurology. 57: 753-754. PMID 11551999 DOI: 10.1212/Wnl.57.5.753 |
0.34 |
|
| 2001 |
Korn T, Toyka K, Hartung H, Jung S. Suppression of experimental autoimmune neuritis by leflunomide. Brain. 124: 1791-1802. PMID 11522581 DOI: 10.1093/Brain/124.9.1791 |
0.327 |
|
| 2001 |
Andorfer B, Kieseier BC, Mathey E, Armati P, Pollard J, Oka N, Hartung HP. Expression and distribution of transcription factor NF-kappaB and inhibitor IkappaB in the inflamed peripheral nervous system. Journal of Neuroimmunology. 116: 226-32. PMID 11438178 DOI: 10.1016/S0165-5728(01)00306-X |
0.317 |
|
| 2001 |
Hartung H. ADEM: distinct disease or part of the MS spectrum? Neurology. 56: 1257-1260. PMID 11376169 DOI: 10.1212/Wnl.56.10.1257 |
0.344 |
|
| 2000 |
Kiefer R, Dangond F, Mueller M, Toyka KV, Hafler DA, Hartung HP. Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies Journal of Neurology Neurosurgery and Psychiatry. 69: 362-368. PMID 10945811 DOI: 10.1046/J.1529-8027.2001.01008-15.X |
0.309 |
|
| 2000 |
Schmidt J, Gold R, Schönrock L, Zettl UK, Hartung H, Toyka KV. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy Brain. 123: 1431-1441. PMID 10869055 DOI: 10.1093/Brain/123.7.1431 |
0.311 |
|
| 2000 |
Archelos JJ, Hartung HP. Pathogenetic role of autoantibodies in neurological diseases. Trends in Neurosciences. 23: 317-27. PMID 10856942 DOI: 10.1016/S0166-2236(00)01575-7 |
0.32 |
|
| 2000 |
Hartung HP, Kieseier BC. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. Journal of Neuroimmunology. 107: 140-7. PMID 10854648 DOI: 10.1016/S0165-5728(00)00225-3 |
0.314 |
|
| 2000 |
Gold R, Oelschläger M, Pepinsky RB, Sommer C, Hartung HP, Toyka KV. Increased lipocortin-1 (annexin-1) expression in the sciatic nerve of Lewis rats with experimental autoimmune neuritis. Acta Neuropathologica. 98: 583-9. PMID 10603033 DOI: 10.1007/S004010051122 |
0.344 |
|
| 1999 |
Wewetzer K, Archelos JJ, Hartung HP, Seilheimer B, Christ B. The monoclonal antibody 23E9 defines a novel developmentally-regulated Schwann cell surface antigen. International Journal of Developmental Neuroscience : the Official Journal of the International Society For Developmental Neuroscience. 17: 715-25. PMID 10568688 DOI: 10.1016/S0736-5748(99)00046-5 |
0.302 |
|
| 1999 |
Hartung HP, Kieseier RC. Antibody responses in the Guillain-Barré syndrome. Journal of the Neurological Sciences. 168: 75-7. PMID 10526186 DOI: 10.1016/S0022-510X(99)00190-2 |
0.308 |
|
| 1999 |
Chan A, Gold R, Giegerich G, Herrmann T, Jung S, Toyka KV, Hartung H. Usage of vβ3.3 T-cell receptor by myelin basic protein-specific encephalitogenic T-cell lines in the Lewis rat Journal of Neuroscience Research. 58: 214-225. PMID 10502278 DOI: 10.1002/(Sici)1097-4547(19991015)58:2<214::Aid-Jnr2>3.0.Co;2-6 |
0.3 |
|
| 1999 |
Noseworthy JH, Gold R, Hartung H. Treatment of multiple sclerosis: recent trials and future perspectives. Current Opinion in Neurology. 12: 279-293. PMID 10499173 DOI: 10.1097/00019052-199906000-00007 |
0.339 |
|
| 1999 |
Kieseier BC, Seifert T, Giovannoni G, Hartung H. Matrix metalloproteinases in inflammatory demyelination Targets for treatment Neurology. 53: 20-20. PMID 10408531 DOI: 10.1212/Wnl.53.1.20 |
0.32 |
|
| 1999 |
Archelos JJ, Previtali SC, Hartung HP. The role of integrins in immune-mediated diseases of the nervous system. Trends in Neurosciences. 22: 30-8. PMID 10088997 DOI: 10.1016/S0166-2236(98)01287-9 |
0.375 |
|
| 1998 |
Archelos JJ, Jung S, Rinner W, Lassmann H, Miyasaka M, Hartung HP. Role of the leukocyte-adhesion molecule L-selectin in experimental autoimmune encephalomyelitis. Journal of the Neurological Sciences. 159: 127-34. PMID 9741395 DOI: 10.1016/S0022-510X(98)00154-3 |
0.327 |
|
| 1998 |
Steck AJ, Schaeren-Wiemers N, Hartung H. Demyelinating Inflammatory Neuropathies, Including Guillain-Barre Syndrome Current Opinion in Neurology. 11: 311-318. PMID 9725076 DOI: 10.1097/00019052-199808000-00006 |
0.349 |
|
| 1998 |
Archelos JJ, Trotter J, Previtali S, Weißbrich B, Toyka KV, Hartung HP. Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis Annals of Neurology. 43: 15-24. PMID 9450764 DOI: 10.1002/Ana.410430107 |
0.343 |
|
| 1998 |
Archelos JJ, Fortwängler T, Hartung HP. Attenuation of experimental autoimmune neuritis in the Lewis rat by treatment with an antibody to L-selectin. Neuroscience Letters. 235: 9-12. PMID 9389583 DOI: 10.1016/S0304-3940(97)00692-7 |
0.318 |
|
| 1997 |
Jung S, Donhauser T, Toyka KV, Hartung H. Propentofylline and Iloprost Suppress the Production of TNF-αby Macrophages but Fail to Ameliorate Experimental Autoimmune Encephalomyelitis in Lewis Rats Journal of Autoimmunity. 10: 519-529. PMID 9451591 DOI: 10.1006/Jaut.1997.0159 |
0.339 |
|
| 1997 |
Fazekas F, Offenbacher H, Hartung H. What Is the Role of Ancillary Investigations in Establishing the Diagnosis of Multiple Sclerosis European Neurology. 38: 255-257. PMID 9434082 DOI: 10.1159/000113390 |
0.32 |
|
| 1997 |
Gaupp S, Hartung HP, Toyka K, Jung S. Modulation of experimental autoimmune neuritis in Lewis rats by oral application of myelin antigens. Journal of Neuroimmunology. 79: 129-37. PMID 9394785 DOI: 10.1016/S0165-5728(97)00115-X |
0.353 |
|
| 1997 |
Gold R, Hartung HP, Lassmann H. T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends in Neurosciences. 20: 399-404. PMID 9292968 DOI: 10.1016/S0166-2236(97)01079-5 |
0.309 |
|
| 1997 |
Archelos JJ, Hartung H. The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications Molecular Medicine Today. 3: 310-321. PMID 9257299 DOI: 10.1016/S1357-4310(97)01066-6 |
0.383 |
|
| 1997 |
Köller H, Siebler M, Hartung HP. Immunologically induced electrophysiological dysfunction: Implications for inflammatory diseases of the CNS and PNS Progress in Neurobiology. 52: 1-26. PMID 9185232 DOI: 10.1016/S0301-0082(96)00065-2 |
0.341 |
|
| 1997 |
Jung S, Toyka KV, Hartung HP. Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats. Neuroscience Letters. 200: 167-70. PMID 9064603 DOI: 10.1016/0304-3940(95)12115-K |
0.334 |
|
| 1997 |
Weishaupt A, Gold R, Gaupp S, Giegerich G, Hartung H, Toyka KV. Antigen therapy eliminates T cell inflammation by apoptosis: Effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2 Proceedings of the National Academy of Sciences of the United States of America. 94: 1338-1343. PMID 9037054 DOI: 10.1073/Pnas.94.4.1338 |
0.339 |
|
| 1997 |
Hartung HP, Willison H, Jung S, Pette M, Toyka KV, Giegerich G. Autoimmune responses in peripheral nerve. Springer Seminars in Immunopathology. 18: 97-123. PMID 8984683 DOI: 10.1007/Bf00792612 |
0.341 |
|
| 1996 |
Zielasek J, Hartung H. Molecular mechanisms of microglial activation. Advances in Neuroimmunology. 6: 191-222. PMID 8876774 DOI: 10.1016/0960-5428(96)00017-4 |
0.328 |
|
| 1996 |
Toyka KV, Hartung HP. Chronic inflammatory polyneuritis and neuropathies. Current Opinion in Neurology. 9: 240-50. PMID 8839619 DOI: 10.1097/00019052-199606000-00016 |
0.357 |
|
| 1996 |
Giovannoni G, Hartung H. The Immunopathogenesis Of Multiple Sclerosis And Guillain-Barre Syndrome Current Opinion in Neurology. 9: 165-177. PMID 8839607 DOI: 10.1097/00019052-199606000-00004 |
0.382 |
|
| 1996 |
Morrissey SP, Deichmann R, Syha J, Simonis C, Zettl U, Archelos JJ, Jung S, Stodal H, Lassmann H, Toyka KV, Haase A, Hartung HP. Partial inhibition of AT-EAE by an antibody to ICAM-1: Clinico-histological and MRI studies Journal of Neuroimmunology. 69: 85-93. PMID 8823379 DOI: 10.1016/0165-5728(96)00064-1 |
0.347 |
|
| 1996 |
Jung S, Toyka K, Hartung H. T cell directed immunotherapy of inflammatory demyelination in the peripheral nervous system : Potent suppression of the effector phase of experimental autoimmune neuritis by anti-CD2 antibodies Brain. 119: 1079-1090. PMID 8813272 DOI: 10.1093/Brain/119.4.1079 |
0.35 |
|
| 1996 |
Jung S, Zielasek J, Köllner G, Donhauser T, Toyka K, Hartung HP. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. Journal of Neuroimmunology. 68: 1-11. PMID 8784254 DOI: 10.1016/0165-5728(96)00051-3 |
0.329 |
|
| 1996 |
Morrissey SP, Stodal H, Zettl U, Simonis C, Jung S, Kiefer R, Lassmann H, Hartung HP, Haase A, Toyka KV. In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis: Quantification of inflammation and oedema Brain. 119: 239-248. PMID 8624685 DOI: 10.1093/Brain/119.1.239 |
0.307 |
|
| 1996 |
Schmidt B, Toyka KV, Kiefer R, Full J, Hartung H, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy Muscle & Nerve. 19: 474-487. PMID 8622727 DOI: 10.1002/(Sici)1097-4598(199604)19:4<474::Aid-Mus8>3.0.Co;2-9 |
0.333 |
|
| 1995 |
Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I. Muscle & Nerve. 18: 137-53. PMID 7823972 DOI: 10.1002/Mus.880180202 |
0.343 |
|
| 1995 |
Hartung HP, Archelos JJ, Zielasek J, Gold R, Koltzenburg M, Reiners KH, Toyka KV. Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology. 45: S22-32. PMID 7783908 DOI: 10.1212/Wnl.45.6_Suppl_6.S22 |
0.32 |
|
| 1995 |
Gold R, Toyka KV, Hartung HP. Synergistic effect of IFN-gamma and TNF-alpha on expression of immune molecules and antigen presentation by Schwann cells. Cellular Immunology. 165: 65-70. PMID 7671325 DOI: 10.1006/Cimm.1995.1187 |
0.308 |
|
| 1995 |
Zettl UK, Gold R, Toyka KV, Hartung H. Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T cells in experimental autoimmune neuritis (EAN) of the Lewis rat. Journal of Neuropathology and Experimental Neurology. 54: 540-547. PMID 7602327 DOI: 10.1097/00005072-199507000-00008 |
0.335 |
|
| 1995 |
Polman CH, Hartung H. The treatment of multiple sclerosis: current and future. Current Opinion in Neurology. 8: 200-209. PMID 7551119 DOI: 10.1097/00019052-199506000-00008 |
0.371 |
|
| 1995 |
Hartung H. Pathogenesis of inflammatory demyelination: implications for therapy. Current Opinion in Neurology. 8: 191-199. PMID 7551118 DOI: 10.1097/00019052-199506000-00007 |
0.306 |
|
| 1995 |
Jung S, Toyka K, Hartung H. Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2. European Journal of Immunology. 25: 1391-1398. PMID 7539758 DOI: 10.1002/Eji.1830250538 |
0.339 |
|
| 1995 |
Hartung H. Basic immunology and the pathogenesis of multiple sclerosis Journal of Neuroimmunology. 17-17. DOI: 10.1016/0165-5728(95)98909-U |
0.379 |
|
| 1994 |
Jung S, Huitinga I, Schmidt B, Zielasek J, Dijkstra CD, Toyka KV, Hartung HP. Selective elimination of macrophages by dichlormethylene diphosphonate-containing liposomes suppresses experimental autoimmune neuritis. Journal of the Neurological Sciences. 119: 195-202. PMID 8277335 DOI: 10.1016/0022-510X(93)90134-K |
0.322 |
|
| 1993 |
Hartung H. Immune‐mediated demyelination Annals of Neurology. 33: 563-567. PMID 8498835 DOI: 10.1002/Ana.410330602 |
0.379 |
|
| 1993 |
Archelos JJ, Mäurer M, Jung S, Toyka KV, Hartung H. Suppression of experimental allergic neuritis by an antibody to the intercellular adhesion molecule ICAM-1 Brain. 116: 1043-1058. PMID 7693297 DOI: 10.1093/Brain/116.5.1043 |
0.346 |
|
| 1993 |
Archelos JJ, Jung S, Mäurer M, Schmied M, Lassmann H, Tamatani T, Miyasaka M, Toyka KV, Hartung H. Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Annals of Neurology. 34: 145-154. PMID 7687838 DOI: 10.1002/Ana.410340209 |
0.336 |
|
| 1992 |
Schmidt B, Stoll G, Meide PVD, Jung S, Hartung H. Transient Cellular Expression Of Γ-Interferon In Myelin-Induced And T-Cell Line-Mediated Experimental Autoimmune Neuritis Brain. 115: 1633-1646. PMID 1486454 DOI: 10.1093/Brain/115.6.1633 |
0.326 |
|
| 1992 |
Hartung HP, Jung S, Stoll G, Zielasek J, Schmidt B, Archelos JJ, Toyka KV. Inflammatory mediators in demyelinating disorders of the CNS and PNS. Journal of Neuroimmunology. 40: 197-210. PMID 1331168 DOI: 10.1016/0165-5728(92)90134-7 |
0.358 |
|
| 1992 |
Stoll G, Hartung H. The role of macrophages in degeneration and immune-mediated demyelination of the peripheral nervous system Advances in Neuroimmunology. 2: 163-179. DOI: 10.1016/S0960-5428(06)80046-X |
0.339 |
|
| 1991 |
Hartung H, Reiners K, Schmidt B, Stoll G, Toyka KV. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: Comparison with other neurological diseases of presumed immunopathogenesis Annals of Neurology. 30: 48-53. PMID 1929228 DOI: 10.1002/Ana.410300110 |
0.31 |
|
| 1990 |
Schmidt B, Stoll G, Hartung H, Heininger K, Schäfer B, Toyka KV. Macrophages but not Schwann cells express Ia antigen in experimental autoimmune neuritis. Annals of Neurology. 28: 70-77. PMID 2375636 DOI: 10.1002/Ana.410280113 |
0.333 |
|
| 1990 |
Hartung H, Schäfer B, Meide PHVD, Fierz W, Heininger K, Toyka KV. The role of interferon-gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system. Annals of Neurology. 27: 247-257. PMID 2158267 DOI: 10.1002/Ana.410270306 |
0.362 |
|
| 1989 |
Seitz RJ, Reiners K, Himmelmann F, Heininger K, Hartung HP, Toyka KV. The blood-nerve barrier in Wallerian degeneration: a sequential long-term study. Muscle & Nerve. 12: 627-35. PMID 2506446 DOI: 10.1002/Mus.880120803 |
0.492 |
|
| 1989 |
Heininger K, Fierz W, Schäfer B, Hartung H, Wehling P, Toyka KV. Electrophysiological Investigations In Adoptively Transferred Experimental Autoimmune Encephalomyelitis In The Lewis Rat Brain. 112: 537-552. PMID 2468392 DOI: 10.1093/Brain/112.2.537 |
0.302 |
|
| 1988 |
Heininger K, Schäfer B, Hartung H, Fierz W, Linington C, Toyka KV. The role of macrophages in experimental autoimmune neuritis induced by a P2-specific T-cell line. Annals of Neurology. 23: 326-331. PMID 3260088 DOI: 10.1002/Ana.410230403 |
0.341 |
|
| 1988 |
Hartung H, Schäfer B, Heininger K, Stoll G, Toyka KV. The role of macrophages and eicosanoids in the pathogenesis of experimental allergic neuritis. Serial clinical, electrophysiological, biochemical and morphological observations. Brain. 111: 1039-1059. PMID 2846115 DOI: 10.1093/Brain/111.5.1039 |
0.353 |
|
| 1988 |
Hartung HP, Schäfer B, Fierz W, Heininger K, Toyka KV. Ciclosporin A prevents P2 T cell line-mediated experimental autoimmune neuritis (AT-EAN) in rat. Neuroscience Letters. 83: 195-200. PMID 2450307 DOI: 10.1016/0304-3940(87)90240-0 |
0.348 |
|
| Show low-probability matches. |